Information Provided By:
Fly News Breaks for March 29, 2018
CGEN
Mar 29, 2018 | 07:22 EDT
Oppenheimer analyst Mark Breidenbach started Compugen with an Outperform rating and $9 price target given a first-in-class PVRIG inhibitor poised to enter the clinic by mid-year.
News For CGEN From the Last 2 Days
There are no results for your query CGEN